

1 The effect of nutritional supplementation on the multi-focal electroretinogram in healthy eyes

2

3 Emma J. Berrow <sup>1</sup> Hannah E. Bartlett <sup>1</sup> Frank Eperjesi <sup>1</sup>

4

5 <sup>1</sup>Ophthalmic Research Group, School of Life and Health Sciences, Aston University, Birmingham,  
6 United Kingdom

7

8 Correspondence to Frank Eperjesi, Ophthalmic Research Group, School of Life and Health Sciences,  
9 Aston University, Aston Triangle, Birmingham, B4 7ET, United Kingdom

10 Tel: +44 121 204 4182

11 Email: [f.eperjesi@aston.ac.uk](mailto:f.eperjesi@aston.ac.uk)

12

13

1 **Abstract**

2 Background

3 Previous studies have demonstrated an increase in macular pigment optical density (MPOD) with lutein  
4 (L)-based supplementation in healthy eyes. However not all studies have assessed whether this  
5 increase in MPOD is associated with changes to other measures of retinal function such as the  
6 multifocal ERG (mfERG). Some studies also fail to report dietary levels of L and zeaxanthin (Z).  
7 Because of the associations between increased levels of L and Z, and reduced risk for AMD, this study  
8 was designed to assess the effects of L-based supplementation on mfERG amplitudes and latencies in  
9 healthy eyes.

10 Methods

11 Multifocal ERG amplitudes, visual acuity (VA), contrast sensitivity (CS), MPOD and dietary levels of L  
12 and Z were assessed in this longitudinal, randomised clinical trial. Fifty two healthy eyes from 52  
13 participants were randomly allocated to receive a L-based supplement (treated group), or no  
14 supplement (non-treated group).

15 Results

16 There were 25 subjects aged 18-77 (mean age  $\pm$  SD;  $48 \pm 17$ ) in the treated group and 27 subjects  
17 aged 21-69 (mean age  $\pm$  SD;  $43 \pm 16$ ) in the non-treated group. All participants attended for three visits.  
18 Visit one at baseline, visit two at 20 weeks and visit three at 40 weeks. A statistically significant increase  
19 in MPOD (F 17.0, p = <0.001) and shortening of mfERG ring 2 P1 latency (F 3.69, p = 0.04) was seen  
20 in the treated group

21 Conclusions

22 Although the results were not clinically significant, the reported trend for improvement in MPOD and  
23 mfERG outcomes warrants further investigation.

24

25 **Keywords:** lutein, macular pigment optical density, multifocal electroretinogram, randomised trial

26

1 **Introduction**

2 Oxidative stress is implicated in the development of age-related macular degeneration (AMD), because  
3 of the high percentage of polyunsaturated fatty acids in the retina, which are readily oxidised [1],  
4 because of: retinal exposure to blue wavelengths of light [2], the retina is highly metabolically active [3]  
5 and phagocytosis within the retinal pigment epithelium is itself a free-radical producing process. As a  
6 result, interest has been raised in the impact of antioxidant supplementation, or dietary modification, on  
7 the onset and progression of AMD. The carotenoids lutein (L) and zeaxanthin (Z) are lipid soluble  
8 antioxidants found within the retina and together make up the macular pigment (MP). They are thought  
9 to reduce oxidative damage by filtering short wavelength blue light within the macula [4] and by  
10 quenching light-induced singlet oxygen and related free radicals [5]. Putative associations between  
11 increased levels of these carotenoids and reduced risk for development of AMD have been suggested  
12 [6-8]. Increased levels of MP optical density (MPOD) have been reported in healthy eyes and eyes with  
13 AMD when supplemented with L and Z [9-17]. Macular pigment reduces with eccentricity in the macular  
14 region [18], although is present at much lower levels in other parts of the retina and other ocular tissues  
15 [19]

16  
17 Improvements in visual function in eyes with early AMD and non-exudative AMD have been reported in  
18 several studies involving carotenoids [20-23]. The Age Related Eye Disease Study 2 (AREDS2)  
19 investigators reported that substituting L and Z for beta-carotene (used in the AREDS 1 formulation) in  
20 a subset of participants resulted in the risk of progression of AMD being reduced by a further 18% over  
21 the 25 % reduction in risk already reported with the AREDS 1 formulation [24].

22 Visual acuity (VA) is commonly used as a measure of visual function in clinical trials, but it is not an  
23 ideal outcome measure as it is subjective, assesses a relatively small retinal area, and doesn't offer an  
24 overview of macular function. A combination of objective and subjective testing is likely to provide a  
25 more robust assessment of visual and retinal function when diagnosing AMD and assessing treatment  
26 outcomes. The multifocal electroretinogram (mfERG) can be used to objectively evaluate specific retinal  
27 areas [25]. It simultaneously assesses electrical potentials from different retinal areas [26], is valuable  
28 in the identification of focal retinal pathology and in monitoring the impact of potential treatments [27]  
29 and can be used to evaluate bipolar cell function, with some contributions from photoreceptors and  
30 retinal ganglion cells [28].

31 The mfERG principally measures cone photoreceptor and bipolar cell function. Tubulin is found in the  
32 receptor axon layer of the cone-abundant fovea where it may selectively binds L and Z [29], leading to  
33 the MPOD increases seen on supplementation. The rationale was that an increase of L and Z binding  
34 to tubulin around the cone photoreceptor axons may have affected cone function which could be  
35 objectively assessed by the mfERG. The aim of this study was to assess the effect of a lutein (L)-based  
36 nutritional supplement on mfERG latency and amplitude in healthy eyes. Secondary outcome measures  
37 were VA, contrast sensitivity (CS) and MPOD.

38

1 **Materials and methods**

2 The research was approved by Aston University Human Sciences Ethical Committee. The tenets of  
3 the declaration of Helsinki [30] and the consolidated standards of reporting trials (CONSORT) checklist  
4 [31] were followed. The study was registered with an International Standard Randomised Controlled  
5 Trial Number (ISRCTN 17842302) and all participants provided informed written consent.

6 The protocol used in this study has previously been reported by our research group in an investigation  
7 of the impact of L and Z supplementation on mfERG in eyes affected by age-related maculopathy [32].  
8 We have included a description of the outcome measures here for completeness.

9 To assess the effects of an L-based supplement in healthy eyes, 52 healthy eyes from 52 participants  
10 were randomly allocated, using the Microsoft Excel random number generator, to receive a L-based  
11 supplement (treated group) or no supplement (non-treated group) at visit 1. All participants attended for  
12 three visits. Visit one at baseline, visit two at 20 weeks and visit three at 40 weeks. All the data was  
13 collected by one of the authors (EJB) who was masked as to which participants had been allocated to  
14 the treated or non-treated group. Participants reported to another of the authors (HEB) for their  
15 randomization code and allocation of supplement tablets where appropriate. Participants were asked  
16 to contact HEB if they had any queries about supplementation. It was explained to each participant that  
17 they should not disclose whether they were in the treated or non-treated group to EJB.

18 The supplement was OcuVite Duo, provided by Bausch and Lomb, Kingston-Upon-Thames, Surrey,  
19 UK. The supplement had two elements. A tablet and a capsule packed in blister packs. The tablets  
20 contained all of the supplement nutrients (see table 1) except for omega 3 which was contained in the  
21 capsules. The dosage was one tablet and one capsule taken orally twice per day. All the nutrients were  
22 within the safe upper levels as defined by the UK Food Standards Agency [33].

23

24 Insert table 1 about here.

25

26 *Sample size*

27 Two previous studies assessing the effects of nutritional supplementation on retinal function using focal  
28 electroretinograms (fERG) [34] and mfERG [22] demonstrated significant results between groups  
29 treated with a nutritional supplement compared with non-treated groups. The fERG study suggested a  
30 sample size of 8 healthy eyes for their healthy older group and 30 eyes for the age-related maculopathy  
31 group [34], which gave a power of 90% at  $\alpha = 0.05$ , for detecting a between group difference of 25 –  
32 30% in amplitude or phase. The mfERG study by the CARMIS investigators, had 27 ARM eyes, 15 in  
33 the supplemented group and 12 in the non-supplemented group [22] and this gave a power of 90% at  
34  $\alpha = 0.05$ , for detecting a between-group difference of  $\geq 55\%$  in mfERG amplitude. A 55% difference in  
35 mfERG amplitude was used as the effect size in sample size calculations for this study [22] (table 2).

1 Insert table 2 about here

2 Because there is paucity in the literature about mfERG latency changes with nutritional  
3 supplementation, effect sizes for mfERG latency were based on a study of vitamin A supplementation  
4 by Dolan et al., who noted a change in central and peripheral P1 latency of 6 ms with vitamin A  
5 supplementation in a single participant case study [35]. For mfERG latency the sample sizes used in  
6 this study gave a power of 80% at the 5% significance level.

7

#### 8 *Inclusion criteria*

9 Suitability for inclusion was evaluated by questionnaire, fundus photographs and VA. For inclusion  
10 participants had to provide written informed consent and were required to have best corrected VA of at  
11 least 0.2 LogMAR (for good mfERG central fixation), clear optical media, no signs of retinal or optic  
12 nerve disease, good general health and not taking medication that affects the retina.

13

#### 14 *Exclusion criteria*

15 Moderate to dense lens opacities, intraocular lens implants, corneal opacities, glaucoma or ocular  
16 hypertension, history of intraocular inflammation, retinal detachment or retinal disease, retinal laser,  
17 diabetes, alcoholism, systemic hypertension, epilepsy, ocular surgery (excluding LASIK/EK), ocular  
18 trauma or neurological disease in the studied eye. Participants with a history of taking medications that  
19 cause retinal toxicity (e.g. topiramate, metronidazole, quinolones, thioridazine, deferoxamine, cisplatin,  
20 oxazepam, vigabatrin, tamoxifen, digoxin) were also excluded.

21

#### 22 Outcome measures

##### 23 *Multifocal Electroretinography*

24 The VERIS science 6.1 (Electrodiagnostic imaging, San Mateo, California, USA) was used to record  
25 the mfERG. The multifocal stimulus, consisting of 61 scaled hexagons was displayed on a high-  
26 resolution, black-and-white cathode ray tube monitor 30cm wide and 30 cm high with a frame rate of  
27 75 Hz. The hexagon stimulus radius subtended approximately 20° of visual field. Each hexagon was  
28 independently alternated between white (200 cd/m<sup>2</sup>) and black (1cd/m<sup>2</sup>) according to a pseudorandom  
29 binary m-sequence [36]. Total recording time was four minutes. Recording time was divided into eight,  
30 30 second segments allowing for participant rests. Fixation target perception was confirmed before  
31 testing commenced. The fixation target size was 1.5% of the area of the central hexagon. Each subject's  
32 vision was optimally corrected with the VERIS system's refractor/camera system. To allow equal  
33 magnification of the stimulus array on the retina, the distance between the participant's eye and  
34 refractor/camera was adjusted by obtaining a sharp image on the observation monitor as per the

1 manufacturer's recommendation. The participant's eye was monitored throughout testing using this  
2 system. Pupils were dilated with tropicamide 1% (Bausch and Lomb, Kingston-Upon-Thames, Surrey,  
3 UK). Gold cup electrodes filled with signa gel (Parker Laboratories, Fairfield, New Jersey, USA) were  
4 applied to the forehead (ground electrode) and approximately 1 cm posterior to the temporal canthus  
5 (reference electrode) of the tested eye after these areas were abraded and cleaned using Nuprep  
6 (Weaver and Company, Aurora, USA). A Dawson Trick Litzkow (DTL) fibre electrode was used as the  
7 active electrode and was placed along the sclera adjacent to the lower eyelid. The participant was asked  
8 to blink to ensure that the electrode found the same natural position for each visit. These electrodes  
9 (Diagnosys UK Ltd) were used for the trial for participant comfort [37] and test-retest reliability [38] while  
10 not obscuring vision. Proxymetacaine hydrochloride 0.5% (Bausch and Lomb, Kingston-Upon-Thames,  
11 Surrey, UK) was instilled to minimise blinking throughout the recording. Any recordings contaminated  
12 with artefact were discarded and repeated. The untested eye was obscured throughout the procedure.  
13 In order to remove signal artefacts and improve the signal to noise ratio but without attenuating mfERG  
14 waveforms, one iteration of artefact removal was performed for each mfERG recording. This removed  
15 small eye movement artefacts. No spatial averaging was performed because this would reduce spatial  
16 resolution as each retinal area stimulated by a hexagon is averaged with 1/6<sup>th</sup> of its neighbouring  
17 hexagons. Thus the waveform of each single retinal area stimulated by a single hexagon would lose  
18 some of its own identity as it was averaged with surrounding waveforms. The mfERG measures were  
19 N1, P1 and N2 latency and N1 P1 amplitude (figure 1) and these were assessed for five rings of retinal  
20 eccentricity (figure 2).

21

22 Insert figures 1 & 2 about here.

23

24 We used a 61 hexagon stimulus as recommended by ISCEV mfERG guidelines to balance the  
25 necessity for participant comfort while providing adequate assessment of macular function [39]. This  
26 also replicates the CARMIS study stimulus type [22].

27

### 28 *Contrast sensitivity*

29 The Pelli-Robson CS test (Clement Clarke International Ltd, Harlow, Essex, UK) was used at 1 m as  
30 per the manufacturer guidelines, with distance refractive correction when required. For consistency CS  
31 was undertaken in the same room for each visit with a background illumination of 142 lux throughout  
32 the trial.

### 33 *Macular pigment optical density*

34 In order to obtain values for retinal accumulation of L and Z., MPOD was obtained using the Macular  
35 Pigment Screener 9000 (MPS) which uses the principle of heterochromatic flicker photometry (HFP).

1 Participants were required to make flicker matches between two wavelengths of light, a blue light  
2 (~465nm), and green light (~530nm). Flicker matches were initially obtained centrally (1°). Flicker rate  
3 was gradually reduced from above the critical fusion frequency (60 Hz) by 6 Hz until the participant  
4 observed the flicker and pressed a response button accordingly. This procedure continued for a series  
5 of pre-set blue-green ratios. Once flicker was detected the luminance of the blue and green light was  
6 changed by 0.2dB increasing the blue light and decreasing the green light while the overall mean  
7 luminance was kept constant. Then the temporal frequency was reset to 60 Hz and the frequency  
8 reduced by 6 Hz again. The sequence continued for a series of blue-green ratios until a V-shaped curve  
9 was obtained. The minimum value of this curve was where the blue and green lights were of equal  
10 luminance. This whole process was repeated peripherally (8°) and again a V-shaped curve was  
11 obtained, providing a minimum value where blue a green lights were equiluminant. Because MP  
12 selectively absorbs blue light and is found centrally but not peripherally, the central minimum value  
13 differed from the peripheral minimum value. Macular Pigment Optical Density was determined by  
14 dividing central minimum blue light intensity by peripheral minimum blue light intensity and log<sub>10</sub> of this  
15 value using MPS computer software. Greater detail of this technique is described by Van Der Veen *et*  
16 *al.* [40]. The background and target luminance was set to 250 cd/m<sup>2</sup>. Participants wore distance glasses  
17 for the test if required, and were instructed to fixate on the central target for obtaining central values.  
18 For peripheral testing participants were asked to blink frequently and adopt a more relaxed fixation at  
19 8° around a 1.75° red fixation target to reduce Troxler's effect.

#### 20 *Visual acuity*

21 LogMAR distance VA testing using a 3 m ETDRS 750 lux retro-illuminated chart was undertaken for  
22 each participant (Sussex vision, Rustington, West Sussex, UK). The eye with the best corrected VA  
23 was determined at the participant's first visit and this eye was assessed for the subsequent visits.

#### 24 *Intraocular pressure*

25 Non-contact intraocular pressure readings (Topcon CT-80 non-contact tonometer, Topcon, Newbury,  
26 Berkshire, UK) were taken prior to instillation of tropicamide 1%.

#### 27 *Fundus photography*

28 A central 45° fundal photograph was taken with the Topcon TRC-NW8, (Topcon, Newbury, Berkshire,  
29 UK) at each visit to determine any change in fundus or media opacity. Participants were instructed to  
30 fixate on a central fixation target for each visit to ensure identical fundus positioning. Any changes in  
31 fundus or media opacity would have resulted in exclusion from the study.

32

#### 33 *Food Diaries*

34 In order to assess whether any changes in outcome measures were due to the L-based nutritional  
35 supplement rather than changes in dietary intake of nutrients, each participant was provided with a

1 food diary. The diary was filled in over two week days and one weekend day. Participants were given  
2 food diaries at visits one and three. The data from the food diaries was analysed using the Weighted  
3 Intake Software Package (WISP, Tinuviel, Llanfechell, Anglesey, UK). Lutein values for foods were  
4 taken from the United States Department of Agriculture (USDA) nutrient databank, release 23  
5 (<http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/SR23/nutrlist/sr23a338.pdf>).

6

## 7 **Results**

8 There were 25 participants (mean age  $\pm$  SD;  $48.68 \pm 17.35$ , range 18-77 years) in the treated group  
9 and 27 (mean age  $\pm$  SD;  $43.93 \pm 16.15$ , range 21-69 years) in the non-treated group. All participants in  
10 the treated group were Caucasian, consisting of 15 females and 10 males. In the non-treated group  
11 there were 20 females and 7 males, 5 South Asians and 22 White. A chi-squared test for independence  
12 demonstrated a significant difference between treated and non-treated groups for ethnicity ( $\chi^2 = 5.122$ ,  
13  $p = 0.024$ ) but not for gender ( $\chi^2 = 1.169$ ,  $p = 0.280$ ). There was no significant difference between  
14 treated and non-treated groups for VA, CS or MPOD.

15 Due to technical difficulties mfERG parameters were not measured for all participants for each visit.  
16 Only 25 participants (15 in the treated group and 10 in the non-treated group) underwent mfERG for all  
17 three visits. However the VA, CS and MPOD were undertaken on all 52 participants. A summary of  
18 differences in baseline characteristics are detailed in table 3 and were analysed using independent-  
19 samples t-tests. Of the 25 participants in the treated group 14 participants returned their baseline dietary  
20 questionnaire (56.0%). Of the 27 participants in the non-treated group 17 returned their baseline dietary  
21 questionnaire (63.0%)

22

23 Insert table 3 about here.

24

25 Each data set was checked for normality using the Shapiro-Wilk statistic which assesses the normality  
26 of distribution of the data. A non-significant result indicates normality and therefore ANOVA was used  
27 for analysis with Tukey's post-hoc range test. When parametric assumptions were not met according  
28 to Shapiro-Wilk tests for normality Kruskal-Wallis one-way analysis of variance for independent groups  
29 was performed with Mann-Whitney U tests demonstrating post-hoc differences between groups.

30 In addition, a mixed between-within subjects ANOVA using SPSS 16.0 software (IBM, North Harbour,  
31 Portsmouth, UK) was conducted to explore the effects of nutritional supplementation compared with  
32 no treatment on retinal function over three time periods using mfERG amplitudes and latencies for  
33 different areas of retinal eccentricity. This provided analysis of the between-subjects variable (treated  
34 and non-treated group), and within-subject variable (time) on the outcome measures (dependent  
35 variable). This test is considered to be tolerant of data distributions that vary from normal [41]. Post-



1 hoc testing was used in lieu of a Bonferroni correction. The significant ANOVA results for mfERG are  
2 displayed in table 4.

3

4 Insert table 4 about here.

5

6 For all mfERG outcome measures there was no significant interaction between treated and non-treated  
7 groups over three time periods or for group (treated versus non-treated) for any mfERG parameters.  
8 There was no significant effect for time for any mfERG parameter except for ring 2 P1 and ring 2 N2  
9 latency (see table 5a). Ring 2 N2 latency became longer over the three visits for both groups. Ring 2  
10 P1 latency became statistically significantly shorter over three visits in the treated group (see table 5b),  
11 although this change was not clinically significant based coefficient of repeatability (CR) values obtained  
12 within our laboratory.

13

14 Insert table 5a about here

15 Insert table 5b about here.

16

17 All participants (25 in the treated group and 27 in the non-treated groups) undertook VA and CS  
18 measurements at all three visits. One participant in the treated group was unable to perform the MPOD  
19 at one of their visits (therefore n=24 for the treated group and n=27 in the non-treated group for this  
20 test). There was no statistically significant difference between treated and non-treated eyes for VA or  
21 CS. There was a significant interaction effect between time and group for MPOD, with MPOD increasing  
22 over the three visits by 0.1 in the treated group compared with a 0.03 reduction in MPOD in the non-  
23 treated group between visits one and three ( $F = 17.00, p < 0.001$ ).

24

25 Insert table 6 about here.

26 Insert figure 3 about here.

27

28 Of the 14 people in the treated group who completed the baseline dietary questionnaire, eight  
29 completed a further questionnaire at visit three. Of the 17 people in the non-treated group who  
30 completed the baseline dietary questionnaire, 10 completed a further questionnaire at visit three. A  
31 paired-samples t-test using SPSS 16.0 demonstrated no significant difference for any of the dietary  
32 components between visits one and three in the treated group and the non-treated group ( $p > 0.05$ ).

1 Compliance was assessed by asking participants to return any boxes of the supplement that were not  
2 taken and remaining tablets were counted. Those who forgot to bring back the tablets were asked to  
3 contact the principle investigator after counting tablets at home. Patient compliance was elicited using  
4 supportive language to minimise the number of participants concealing supplement non-adherence  
5 [42], and reporting lower levels of remaining tablets than was actually the case. The sole reason for  
6 non-adherence was forgetfulness. A one way ANOVA using SPSS 16.0 found no statistically significant  
7 difference between groups for supplement compliance during the study (see table 7) ( $F = 0.40$ ,  $p =$   
8  $0.68$ ).

9

10 Insert table 7 about here

11

## 12 **Discussion**

13 This randomised controlled trial was designed to assess the effect of a nutritional supplement containing  
14 12 mg L, 0.6 mg Z, 150 mg vitamin C, 15 mg of vitamin E, 400  $\mu\text{g}$  copper, 20 mg zinc and 1080 mg  
15 omega-3 fatty acids on objective and subjective clinical measures of visual and retinal function in  
16 healthy eyes.

17 There was a statistically significant increase in MPOD and shortening of ring 2 P1 latency, with  
18 supplementation. It is important to also consider the clinical significance of these findings. Clinical  
19 significance is related to the reliability of the instrumentation being used. The reliability is quantified  
20 using the coefficient of repeatability and was calculated for each outcome measure within our  
21 laboratory. If the change in outcome recorded is less than the coefficient of repeatability, then it is not  
22 possible to conclude that the change is not simply due to measurement noise. Although neither of these  
23 statistically significant changes can be considered clinically significant based on coefficient of  
24 repeatability data from our laboratory, the trends demonstrated may warrant further investigation.

25 Many studies have demonstrated an increase in MPOD with L-based supplementation in healthy eyes  
26 [9-11,43,12-17]. However not all studies have assessed whether this increased retinal accumulation of  
27 MP is associated with changes to other measures of visual and retinal function such as CS, VA or  
28 mfERG [11,10,43,13-15,17]. Some studies also failed to report dietary levels of L and Z during  
29 supplementation [10,11,13-16].

30 There have been conflicting results within the literature with regards to the effects of nutritional  
31 supplementation on visual function in healthy eyes. A study by Sasamoto *et al.* assessing the effects of  
32 a nutritional supplement on MPOD and visual function showed that MPOD did not significantly increase  
33 over 12 months, although improvements in CS were seen [44]. It is difficult to compare this with the  
34 current study as different methods of assessing MPOD (autofluorescence spectrometry) and CS (area  
35 under the log contrast sensitivity function) were used, and supplement formulation (6mg L), ethnicity

1 (Japanese) and study design were not the same. Also some of the participants in Sasamoto *et al*'s  
2 study consisted of healthy fellow eyes of those with AMD or central serous chorioretinopathy which may  
3 have been subject to subtle retinal changes not clinically visible.

4 The Collaborative Optical Macular Pigment Assessment Study (COMPASS) investigators concluded  
5 that supplementing with 12 mg of L, 1 mg of Z and antioxidants in healthy eyes significantly increased  
6 MPOD over 12 months, but this did not correspond with an improvement in VA or photopic CS [45].  
7 This is in agreement with our study but a different method of CS assessment was used (contrast  
8 sensitivity function), the sample size was larger at 121 subjects and the supplement formulation differed.

9 A 12 week study of 37 healthy eyes found no statistically significant improvement in VA or central CS  
10 when supplementing with 6 or 12 mg of L [46]. Improvements were noted at wider fields of CS analysis.  
11 This study differed from the current one in supplement formulation, ethnicity (Chinese) and methods of  
12 CS (automated contrast glare tester) assessment.

13 A study by Bartlett and Eperjesi concluded that supplementing with 6 mg of L combined with vitamins  
14 and minerals did not improve CS or VA over 9 or 18 months [47]. The same methods of VA and CS  
15 assessment were used, and a similar study design as the current study although supplement  
16 formulation differed.

17 To the authors' knowledge, the literature provides no information with regards to the effects of nutritional  
18 supplementation on mfERG measures in healthy eyes. Ring 2 P1 latency of the mfERG became  
19 statistically significantly shorter over time in those taking the supplement. Although there was a  
20 difference between treated and non-treated groups for ethnicity for the current study there is no reason  
21 to believe that the results would have been different if the treated group had contained similar numbers  
22 of Asians as the non-treated group.

23 The CARMIS investigators found that a 10 mg L-based supplement over 12 months increased N1P1  
24 amplitudes in rings 1 and 2 of the mfERG in 15 eyes with ARM or non-central geographic atrophy [22].  
25 We did not find any mfERG amplitude increase in our healthy supplemented eyes, although the  
26 supplement composition was not the same as the CARMIS supplement formula. Unlike the current  
27 study, the CARMIS investigators did not report dietary levels of L and Z throughout the study period,  
28 thus it is difficult to determine if the mfERG changes seen were due supplementary or dietary changes  
29 in L and Z. Retinal accumulation of L and Z (MPOD) was not measured in the CARMIS study, thus it is  
30 impossible to ascertain if increased retinal levels of L and Z were related to the increased central mfERG  
31 amplitudes reported in their study.

32 The study formulation also contained omega-3 essential fatty acids, which may also be implicated in  
33 the statistically significant change in Ring 2 P1 latency. Observational studies support the hypothesis  
34 that omega 3 poly-unsaturated fatty acids (PUFA) are protective in the eye. A 2008 meta-analysis of  
35 epidemiological studies reported that a high intake of omega-3 fatty acids and fish intake at least twice  
36 a week may reduce the primary risk of early and late AMD by up to 38%. [48]. In a 5-year follow-up  
37 study of the Blue Mountains Eye Study cohort, fish consumption at least once a week was associated

1 with a 40% reduction in incident early age-related macular degeneration, and more frequent  
2 consumption of fish (3 times a week) was found to be protective against late ARM. [49]. Other studies  
3 have found similar findings. [24], [25] [26], [16]. Some prospective studies also reveal a decreased  
4 likeliness of AMD progression in those with early AMD. [7, 17, 18].

5

### 6 *Study limitations*

7 The age range of participants (18-77 years) may have implications for the interpretation of results, as it  
8 has been demonstrated that mfERG parameters are correlated with age [50,51]. In addition, the use of  
9 ring averages to estimate effects may have resulted in underestimation of the true magnitude of effect  
10 due to age effect variability between individual rings [52].

11 Food diaries were prospective and were completed over several days in order to provide detailed dietary  
12 information. Return rates were low. A recall food diary may have provided a greater number of returned  
13 questionnaires as participants could have completed these during their visits. However, this may not  
14 have been as accurate due to participants having to remember their food intake over a three day period.  
15 Serum analysis would have provided a more accurate overview of compliance and dietary habits. It  
16 would have been useful to record body mass index (BMI) for all participants, as a BMI greater than 27  
17 has been associated with reduced retinal uptake of Z and so may have confounded the results [53].  
18 Use of a placebo for the non-treated group would have strengthened the study, but the cost of this was  
19 prohibitive.

20 Using a combined-nutrient formulation does not allow for any evaluation of the impact of individual  
21 nutrients. It is common, however, to find nutritional supplements that contain a combination of several  
22 nutrients; this is because of the synergistic relationships between them. Examples include copper and  
23 zinc combinations required for copper-zinc superoxide dismutase, a part of the antioxidant system  
24 within the retinal pigment epithelium and retina [54], and increased bioavailability of L with the addition  
25 of certain fats, including olive and peanut oils [55,56]. Use of multi-nutrient formulations in AMD is  
26 supported by the results of the AREDS, in which zinc and antioxidants reduced the relative risk of  
27 developing advanced AMD by 21% and 17% respectively. When zinc and antioxidants were combined,  
28 the risk reduced further to 25% [57].

29

### 30 **Conclusion**

31 The current study adds to literature in several ways. It expands on the CARMIS study by assessing the  
32 effects of an L-based supplement in healthy eyes. The pertinence of this lies in any potential protective  
33 role the supplement may have in delaying onset of AMD in healthy eyes. The assessment of dietary  
34 intake over the study period is important in such studies so as to be able to attribute any changes in  
35 study outcome measures to supplementation rather than diet. Subjective measures of visual function  
36 were undertaken alongside objective measures of retinal function in order to assess whether

1 improvements in retinal function may have been associated with improved subjective measures of  
2 visual function.

3 The statistically significant accumulation of L and Z within the retina, and improved retinal function in  
4 healthy eyes with L-based supplementation are encouraging. It may be that further beneficial effects of  
5 accumulated MP on retinal and visual function may be witnessed over a longer term and/or with higher  
6 supplement dosage.

7

8 **Acknowledgements:** Bausch & Lomb provided financial support in the form of PhD funding. The  
9 sponsor had no role in the design or conduct of this research.

10 **Conflict of Interest:** All authors certify that they have no affiliations with or involvement in any  
11 organization or entity with any financial interest (such as honoraria; educational grants; participation in  
12 speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity  
13 interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as  
14 personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or  
15 materials discussed in this manuscript.

16

17 **Ethical approval:** All procedures performed in studies involving human participants were in accordance  
18 with the ethical standards of the institutional and/or national research committee and with the 1964  
19 Helsinki declaration and its later amendments or comparable ethical standards.

20 **Informed consent:** Informed consent was obtained from all individual participants included in the study.

21

## 22 **References**

23

24 1. Stephen B, Hui-Hiang K, Phil M, David H, Michael B Articles: The Role of Oxidative Stress in the  
25 Pathogenesis of Age-Related Macular Degeneration. *Survey of Ophthalmology* 45:115-134.  
26 doi:10.1016/S0039-6257(00)00140-5

27 2. Ham Jr WT, Ruffolo Jr JJ, Mueller HA, Clarke AM, Moon ME (1978) Histologic analysis of  
28 photochemical lesions produced in rhesus retina by short-wavelength light. *Investigative*  
29 *Ophthalmology and Visual Science* 17 (10):1029-1035

30 3. Levin LA, Kaufman PL, Alm A, Adler FH (2011) *Adler's physiology of the eye* / editors: Leonard A.  
31 Levin ... [et al.] ; managing editors: Paul L. Kaufman, Albert Alm. Edinburgh : Saunders/Elsevier,  
32 c2011.

33 11th ed.,

34 4. Snodderly DM, Auran J, Delori F (1984) The macular pigment II. Spatial distribution in primate  
35 retinas. *Investigative Ophthalmology and Visual Science* 25:674-685

36 5. Li B, Ahmed F, Bernstein PS (2010) Studies on the singlet oxygen scavenging mechanism of  
37 human macular pigment. *Archives of Biochemistry and Biophysics* 504 (1):56-60. doi:S0003-  
38 9861(10)00303-6 [pii]

- 1 10.1016/j.abb.2010.07.024
- 2 6. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD (2001) Lutein and  
3 zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national  
4 health and nutrition examination survey. *American Journal of Epidemiology* 153 (5):424-432
- 5 7. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller  
6 J, Miller DT, Yannuzzi LA, Willett W (1994) Dietary carotenoids, vitamin A,C and E and advanced  
7 age-related macular degeneration. *Journal of the American Medical Association* 272 (18):1413-1420
- 8 8. EDCCS Group (1993) Antioxidant status and neovascular age-related macular degeneration. Eye  
9 Disease Case-Control Study Group. *Archives of ophthalmology* 111 (1):104-109
- 10 9. Nolan JM, Loughman J, Akkali MC, Stack J, Scanlon G, Davison P, Beatty S (2011) The impact of  
11 macular pigment augmentation on visual performance in normal subjects: COMPASS. *Vision*  
12 *Research*. doi:S0042-6989(10)00594-8 [pii]
- 13 10.1016/j.visres.2010.12.016
- 14 10. Bone RA, Landrum JT (2010) Dose-dependent response of serum lutein and macular pigment  
15 optical density to supplementation with lutein esters. *Archives of Biochemistry and Biophysics* 504  
16 (1):50-55. doi:10.1016/j.abb.2010.06.019
- 17 11. Connolly EE, Beatty S, Thurnham DI, Loughman J, Howard AN, Stack J, Nolan JM (2010)  
18 Augmentation of macular pigment following supplementation with all three macular carotenoids: an  
19 exploratory study. *Current Eye Research* 35 (4):335-351. doi:10.3109/02713680903521951
- 20 12. Stringham JM, Hammond BR (2008) Macular pigment and visual performance under glare  
21 conditions. *Optometry and Vision Science* 85 (2):82-88
- 22 13. Wenzel AJ, Sheehan JP, Gerweck C, Stringham JM, Fuld K, Curran-Celentano J (2007) Macular  
23 pigment optical density at four retinal loci during 120 days of lutein supplementation. *Ophthalmic and*  
24 *physiological optics : the journal of the British College of Ophthalmic Opticians* 27 (4):329-335.  
25 doi:10.1111/j.1475-1313.2007.00495.x
- 26 14. Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M,  
27 Pauleikhoff D (2007) Changes in macular pigment optical density and serum concentrations of its  
28 constituent carotenoids following supplemental lutein and zeaxanthin: The LUNA study. *Experimental*  
29 *Eye Research* 84 (4):718-728. doi:10.1016/j.exer.2006.12.010
- 30 15. Schalch W, Cohn W, Barker FM, Kopcke W, Mellerio J, Bird AC, Robson AG, Fitzke FF, van Kuijk  
31 FJ (2007) Xanthophyll accumulation in the human retina during supplementation with lutein or  
32 zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. *Archives of Biochemistry and*  
33 *Biophysics* 458 (2):128-135. doi:10.1016/j.abb.2006.09.032
- 34 16. Rodriguez-Carmona M, Kvensakul J, Harlow JA, Kopcke W, Schalch W, Barbur JL (2006) The  
35 effects of supplementation with lutein and/or zeaxanthin on human macular pigment density and  
36 colour vision. *Ophthalmic and physiological optics : the journal of the British College of Ophthalmic*  
37 *Opticians* 26 (2):137-147. doi:10.1111/j.1475-1313.2006.00386.x
- 38 17. Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S (2004) Plasma and macular  
39 responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study.  
40 *Experimental Eye Research* 79 (1):21-27. doi:10.1016/j.exer.2004.03.001
- 41 S0014483504000843 [pii]
- 42 18. Hammond BR, Wooten BR, Snodderly DM (1997) Individual variations in the spatial profile of  
43 human macular pigment. *Journal of the Optical Society of America a-Optics Image Science and*  
44 *Vision* 14 (6):1187-1196

- 1 19. Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao D-Y, Katz NB (2001) Identification and  
2 quantitation of carotenoids and their metabolites in the tissues of the human eye. *Experimental eye*  
3 *research* 72 (3):215-223
- 4 20. Cangemi FE (2007) TOZAL Study: an open case control study of an oral antioxidant and omega-3  
5 supplement for dry AMD. *Biomed Central Ophthalmology* 7:3. doi:1471-2415-7-3 [pii]
- 6 10.1186/1471-2415-7-3
- 7 21. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tspursky M, Nyland J  
8 (2004) Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation  
9 in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein  
10 Antioxidant Supplementation Trial). *Optometry* 75 (4):216-230
- 11 22. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S (2008) Carotenoids and  
12 antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after  
13 1 year. *Ophthalmology* 115 (2):324-333 e322. doi:S0161-6420(07)00581-7 [pii]
- 14 10.1016/j.ophtha.2007.05.029
- 15 23. Richer S (1999) ARMD--pilot (case series) environmental intervention data. *Journal of the*  
16 *American Optometric Association* 70 (1):24-36
- 17 24. Chew EY, Clemons TE, SanGiovanni JP, Danis R, Ferris FL, Elman M, Antoszyk A, Ruby A, Orth  
18 D, Bressler S, Fish G, Hubbard B, Klein M, Chandra S, Blodi B, Domalpally A, Friberg T, Wong W,  
19 Rosenfeld P, Agron E, Toth C, Bernstein P, Sperduto R (2013) Lutein plus Zeaxanthin and Omega-3  
20 Fatty Acids for Age-Related Macular Degeneration The Age-Related Eye Disease Study 2 (AREDS2)  
21 Randomized Clinical Trial. *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
22 309:2005-2015
- 23 25. Hood DC, Odel JG, Chen CS, Winn BJ (2003) The multifocal electroretinogram. *Journal of Neuro-*  
24 *Ophthalmology* 23 (3):225-235
- 25 26. Sutter EE, Tran D (1992) THE FIELD TOPOGRAPHY OF ERG COMPONENTS IN MAN .1. THE  
26 PHOTOPIC LUMINANCE RESPONSE. *Vision Research* 32 (3):433-446
- 27 27. Karanjia R, Eng KT, Gale J, Sharma S, ten Hove MW (2008) Electrophysiological effects of  
28 intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration.  
29 *British Journal of Ophthalmology* 92 (9):1248-1252. doi:10.1136/bjo.2008.138800
- 30 28. Hood DC, Frishman LJ, Saszik S, Viswanathan S (2002) Retinal origins of the primate multifocal  
31 ERG: Implications for the human response. *Investigative Ophthalmology and Visual Science* 43  
32 (5):1673-1685
- 33 29. Bernstein PS, Balashov NA, Tsong ED, Rando RR (1997) Retinal tubulin binds macular  
34 carotenoids. *Investigative Ophthalmology and Visual Science* 38 (1):167-175
- 35 30. Declaration of Helsinki. Ethical principles for medical research involving human subjects (2009).  
36 *Journal of the Indian Medical Association* 107 (6):403-405
- 37 31. Schulz K, Altman D, Moher D, Group tC (2010) CONSORT 2010 Statement: updated guidelines  
38 for reporting parallel group randomised trials. *Biomed Central Medicine* 8 (1):18
- 39 32. Berrow E, Bartlett H, Eperjesi F, Gibson J (2013) The effects of a lutein-based supplement on  
40 objective and subjective measures of retinal and visual function in eyes with age-related maculopathy  
41 – a randomised controlled trial. *British Journal of Nutrition* 109:2008-2014
- 42 33. FSA (2003) Expert group on vitamins and minerals - Safe upper levels for vitamins and minerals.  
43 Food standards agency,

- 1 34. Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P (2003) Influence of short-term  
2 antioxidant supplementation on macular function in age-related maculopathy. A pilot study including  
3 electrophysiologic assessment. *Ophthalmology* 110 (1):51-60
- 4 35. Dolan F, Sandinha T, Purdy A, Parks S, Keating D (2006) Vitamin A Deficiency Modifies the  
5 mfERG: A Case Study of Rod Influence on the mfERG. *Documenta Ophthalmologica* 112 (1):31-34.  
6 doi:10.1007/s10633-006-0002-1
- 7 36. Sutter EE (1991) THE FAST M-TRANSFORM - A FAST COMPUTATION OF CROSS-  
8 CORRELATIONS WITH BINARY M-SEQUENCES. *Siam Journal on Computing* 20 (4):686-694
- 9 37. Beeler P, Barthelmes D, Sutter FK, Helbig H, Fleischhauer JC (2007) Comparison of performance  
10 and patient satisfaction of two types of ERG electrodes. *Klinische Monatsblätter Fur Augenheilkunde*  
11 224 (4):265-268. doi:10.1055/s-2007-962856
- 12 38. Meigen T, Friedrich A (2002) [The reproducibility of multifocal ERG recordings]. *Ophthalmologe*  
13 99 (9):713-718. doi:10.1007/s00347-002-0630-0
- 14 39. Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, Palmowski-Wolfe AM (2008) ISCEV  
15 guidelines for clinical multifocal electroretinography (2007 edition). *Documenta Ophthalmologica* 116  
16 (1):1-11. doi:10.1007/s10633-007-9089-2
- 17 40. van der Veen RL, Berendschot TT, Hendrikse F, Carden D, Makridaki M, Murray IJ (2009) A new  
18 desktop instrument for measuring macular pigment optical density based on a novel technique for  
19 setting flicker thresholds. *Ophthalmic and Physiological Optics* 29 (2):127-137. doi:OPO618 [pii]  
20 10.1111/j.1475-1313.2008.00618.x
- 21 41. Gravetter F, Wallnau L (2000) *Statistics for the behavioural sciences*. 5th edition edn. Wadsworth,  
22 Belmont, CA
- 23 42. Hahn SR (2009) Patient-Centered Communication to Assess and Enhance Patient Adherence to  
24 Glaucoma Medication. *Ophthalmology* 116 (11):S37-S42. doi:10.1016/j.ophtha.2009.06.023
- 25 43. Johnson EJ, Chung HY, Caldarella SM, Snodderly DM (2008) The influence of supplemental  
26 lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. *The American*  
27 *Journal of Clinical Nutrition* 87 (5):1521-1529
- 28 44. Sasamoto Y, Gomi F, Sawa M, Tsujikawa M, Nishida K (2011) Effect of 1-year lutein  
29 supplementation on macular pigment optical density and visual function. *Graefe's archive for clinical*  
30 *and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle*  
31 *Ophthalmologie*. doi:10.1007/s00417-011-1780-z
- 32 45. Nolan JM, Kenny R, O'Regan C, Cronin H, Loughman J, Connolly EE, Kearney P, Loane E,  
33 Beatty S (2010) Macular pigment optical density in an ageing Irish population: The Irish Longitudinal  
34 Study on Ageing. *Ophthalmic Research* 44 (2):131-139. doi:000315531 [pii]  
35 10.1159/000315531
- 36 46. Ma L, Lin XM, Zou ZY, Xu XR, Li Y, Xu R (2009) A 12-week lutein supplementation improves  
37 visual function in Chinese people with long-term computer display light exposure. *British Journal of*  
38 *Nutrition* 102 (2):186-190. doi:10.1017/s0007114508163000
- 39 47. Bartlett HE, Eperjesi F (2008) A randomised controlled trial investigating the effect of lutein and  
40 antioxidant dietary supplementation on visual function in healthy eyes. *Clinical Nutrition* 27 (2):218-  
41 227. doi:10.1016/j.clnu.2008.01.003
- 42 48. Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH (2008) Dietary omega-3 fatty acid and  
43 fish intake in the primary prevention of age-related macular degeneration: a systematic review and  
44 meta-analysis. *Arch Ophthalmol* 126 (6):826-833. doi:10.1001/archophth.126.6.826



- 1 49. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P (2006) Dietary fatty acids and the  
2 5-year incidence of age-related maculopathy. *Arch Ophthalmol* 124 (7):981-986.  
3 doi:10.1001/archoph.124.7.981
- 4 50. Mohidin N, Yap M, Jacobs R (1999) Influence of age on the multifocal electroretinography.  
5 *Ophthalmic and Physiological Optics* 19 (6):481-488
- 6 51. Karpe G, Rickenbach K, Thomasson S (1949) The clinical electroretinogram. I. The normal  
7 electroretinogram above fifty years of age. *Acta ophthalmologica* 28 (3):301-305
- 8 52. Tzekov RT, Gerth C, Werner JS (2004) Senescence of human multifocal electroretinogram  
9 components: a localized approach. *Graefes Archive for Clinical and Experimental Ophthalmology* 242  
10 (7):549-560
- 11 53. Nolan JM, Stack J, O'Connell E, Beatty S (2007) The relationships between macular pigment  
12 optical density and its constituent carotenoids in diet and serum. *Investigative Ophthalmology &  
13 Visual Science* 48 (2):571-582. doi:10.1167/iovs.06-0864
- 14 54. Erie JC, Good JA, Butz JA, Pulido JS (2009) Reduced zinc and copper in the retinal pigment  
15 epithelium and choroid in age-related macular degeneration. *American Journal of Ophthalmology* 147  
16 (2):276-282. doi:10.1016/j.ajo.2008.08.014
- 17 55. O'Connell O, Ryan L, O'Sullivan L, Aherne-Bruce SA, O'Brien NM (2008) Carotenoid  
18 micellarization varies greatly between individual and mixed vegetables with or without the addition of  
19 fat or fiber. *International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin-  
20 und Ernährungsforschung Journal international de vitaminologie et de nutrition* 78 (4-5):238-246.  
21 doi:10.1024/0300-9831.78.45.238
- 22 56. Lakshminarayana R, Raju M, Keshava Prakash MN, Baskaran V (2009) Phospholipid, oleic acid  
23 micelles and dietary olive oil influence the lutein absorption and activity of antioxidant enzymes in rats.  
24 *Lipids* 44 (9):799-806. doi:10.1007/s11745-009-3328-0
- 25 57. The AREDS Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose  
26 supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration  
27 and vision loss - AREDS Report No. 8. *Archives of ophthalmology* 119 (10):1417-1436
- 28 58. Elliott DB, Sheridan M (1988) The use of accurate visual acuity measurements in clinical anti-  
29 cataract formulation trials. *Ophthalmic & physiological optics : the journal of the British College of  
30 Ophthalmic Opticians* 8 (4):397-401
- 31 59. Arditi A, Cagenello R (1993) On the statistical reliability of letter-chart visual acuity measurements.  
32 *Investigative Ophthalmology & Visual Science* 34 (1):120-129
- 33 60. Bailey IL, Bullimore MA, Raasch TW, Taylor HR (1991) Clinical grading and the effects of scaling.  
34 *Investigative Ophthalmology & Visual Science* 32 (2):422-432
- 35 61. Lovie-Kitchin JE (1988) Validity and reliability of visual acuity measurements. *Ophthalmic &  
36 physiological optics : the journal of the British College of Ophthalmic Opticians* 8 (4):363-370
- 37 62. Reeves BC, Wood JM, Hill AR (1991) Vistech VCTS 6500 charts--within- and between-session  
38 reliability. *Optometry and vision science : official publication of the American Academy of Optometry*  
39 68 (9):728-737
- 40 63. Elliott DB, Sanderson K, Conkey A (1990) The reliability of the Pelli-Robson contrast sensitivity  
41 chart. *Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians* 10  
42 (1):21-24
- 43 64. Bartlett H, Stainer L, Singh S, Eperjesi F, Howells O (2010) Clinical evaluation of the MPS 9000  
44 Macular Pigment Screener. *Br J Ophthalmol* 94 (6):753-756. doi:10.1136/bjo.2009.175901

1

2

1 **Tables**

2

| <b>Ingredient</b> | <b>Safe upper levels per day [33]</b> | <b>Dosage</b> |
|-------------------|---------------------------------------|---------------|
| Vitamin C         | 1000 mg (guidance only)               | 150 mg        |
| Copper            | 10 mg                                 | 400 µg        |
| Vitamin E         | 540 mg                                | 15 mg         |
| Zinc              | 25 mg                                 | 20mg          |
| Lutein            | none established                      | 12 mg         |
| Zeaxanthin        | none established                      | 0.6 mg        |
| Omega-3           | none established                      | 1080 mg       |

3 Table 1: supplement composition. These amounts were provided by taking two tablets and two capsules  
4 per day.

5

1

|  | VA<br>(logMAR)     | CS<br>(log units) | MPOD              | Central mfERG<br>N1P1 amplitude<br>(nV/deg <sup>2</sup> ) | Central mfERG P1<br>latency (ms) |
|--|--------------------|-------------------|-------------------|---|----------------------------------|
| Mean   | -0.11              | 1.89              | 0.39              | 173.17  | 29.09                            |
| Standard deviation<br>(SD)                                 | 0.11               | 0.12              | 0.16              | 50.12   | 1.43                             |
| Effect size (E)  | 0.10 <sup>^^</sup> | 0.30 <sup>^</sup> | 0.33 <sup>*</sup> | 95.24 <sup>**</sup>                                       | 6.00 <sup>***</sup>              |
| E/S  | 0.91               | 2.50              | 2.06              | 1.90  | 4.20                             |
| (E/SD) <sup>2</sup>  | 0.83               | 6.25              | 4.25              | 3.61  | 17.60                            |
| Sample size =<br>16/(E/SD) <sup>2</sup><br><br>(two sided) | 19                 | 3                 | 4                 | 4   | 1                                |

2 Table 2: Group sizes required to have 80% power at the 5% significance level for VA, CS, mfERG  
 3 amplitude and MPOD for healthy eyes. The mean and standard deviation (SD) data were calculated  
 4 from 52 healthy eyes at visit 1.

5 <sup>^^</sup> Based on VA repeatability studies [58-62].

6 <sup>^</sup> Based on Elliot *et al's* paper [63].

7 <sup>\*</sup> Repeatability value from Bartlett *et al's* of HFP repeatability paper [64]

8 <sup>\*\*</sup> Based on Parisi *et al's* paper of a 55% change in mfERG amplitude [22]

9 <sup>\*\*\*</sup> Based on Dolan *et al's* paper [35]

10

1

| Variable                           | Treated group<br>(n=25) |         | Non-treated group<br>(n=27) |         | t     | p    |
|------------------------------------|-------------------------|---------|-----------------------------|---------|-------|------|
|                                    | mean                    | ±SD     | mean                        | ±SD     |       |      |
| Age (years)                        | 48.68                   | 17.35   | 43.93                       | 16.15   | 1.02  | 0.31 |
| Smoking (pack-years)*              | 2.02                    | 3.32    | 2.73                        | 6.08    | -0.52 | 0.61 |
| Spherical equivalent (D)           | 0.64                    | 2.21    | 0.22                        | 2.24    | 0.68  | 0.50 |
| Axial length (mm)                  | 23.31                   | 1.12    | 23.68                       | 1.07    | -1.23 | 0.23 |
| Baseline dietary questionnaires    | Treated group<br>(n=14) |         | Non-treated group<br>(n=17) |         | t     | p    |
|                                    | mean                    | ±SD     | mean                        | ±SD     |       |      |
| Dietary copper (mg)                | 1.37                    | 0.87    | 1.00                        | 0.38    | 1.60  | 0.12 |
| Dietary zinc (mg)                  | 7.40                    | 2.08    | 6.84                        | 1.91    | 0.78  | 0.44 |
| Dietary retinol (µg)               | 705.57                  | 1584.91 | 207.12                      | 122.74  | 1.17  | 0.26 |
| Dietary carotene (µg)              | 1789.71                 | 1216.07 | 2557.59                     | 2272.45 | -1.20 | 0.24 |
| Dietary Vitamin E (mg)             | 3.67                    | 1.25    | 5.09                        | 2.26    | -1.45 | 0.17 |
| Dietary Vitamin C (mg)             | 85.43                   | 64.73   | 102.59                      | 60.16   | -0.76 | 0.45 |
| Dietary lutein and zeaxanthin (µg) | 1295.33                 | 924.07  | 2016.29                     | 2044.30 | -1.30 | 0.21 |
| Dietary Omega 3 (g)                | 0.17                    | 0.12    | 0.15                        | 0.15    | 0.30  | 0.76 |

2 Table 3: A summary of baseline characteristics for treated and non-treated healthy eyes using  
 3 independent-samples t-tests.

4

| Outcome measure   | Main effect: time |       | Main effect: group<br>(treated/non-treated) |       | Interaction effect |       |
|-------------------|-------------------|-------|---|-------|--------------------|-------|
|                   | F                 | p     | F   | p     | F                  | p     |
| Ring 2 P1 latency | 5.067             | 0.015 | 0.188                                       | 0.668 | 3.694              | 0.041 |
| Ring 2 N2 latency | 3.622             | 0.044 | 0.191                                       | 0.666 | 0.095              | 0.910 |

1 Table 4: Significant results (shaded) from a mixed between-within ANOVA for mfERG N1P1  
2 amplitude, N1 latency, P1 latency and N2 latency over three visits for five areas of retinal eccentricity  
3 between treated and non-treated healthy eyes. The shaded areas indicate statistical significance.

4

1

| Outcome measure        | Main effect: time |       | Main effect: group<br>(treated/non-treated) |       | Interaction effect |       |
|------------------------|-------------------|-------|---|-------|--------------------|-------|
|                        | F                 | p     | F   | p     | F                  | p     |
| Ring 1 N1-P1 amplitude | 0.311             | 0.736 | 0.617                                       | 0.440 | 0.067              | 0.935 |
| Ring 2 N1-P1 amplitude | 1.642             | 0.216 | 0.058                                       | 0.812 | 0.034              | 0.966 |
| Ring 3 N1-P1 amplitude | 1.659             | 0.213 | 0.112                                       | 0.741 | 0.063              | 0.939 |
| Ring 4 N1-P1 amplitude | 1.408             | 0.266 | 0.212                                       | 0.650 | 0.068              | 0.934 |
| Ring 5 N1-P1 amplitude | 0.007             | 0.993 | 1.894                                       | 0.182 | 0.193              | 0.826 |
| Ring 1 N1 latency      | 1.203             | 0.319 | 1.072                                       | 0.311 | 0.957              | 0.400 |
| Ring 2 N1 latency      | 0.579             | 0.569 | 1.868                                       | 0.185 | 0.253              | 0.778 |
| Ring 3 N1latency       | 0.196             | 0.823 | 0.280                                       | 0.602 | 0.513              | 0.606 |
| Ring 4 N1 latency      | 0.695             | 0.510 | <0.001                                      | 0.998 | 0.101              | 0.905 |
| Ring 5 N1 latency      | 0.481             | 0.624 | 0.057                                       | 0.813 | 0.543              | 0.588 |
| Ring 1 P1 latency      | 3.172             | 0.062 | 1.973                                       | 0.174 | 1.294              | 0.294 |
| Ring 2 P1 latency      | 5.067             | 0.015 | 0.188                                       | 0.668 | 3.694              | 0.041 |
| Ring 3 P1 latency      | 1.401             | 0.268 | 0.365                                       | 0.552 | 0.118              | 0.889 |
| Ring 4 P1 latency      | 1.046             | 0.368 | 0.011                                       | 0.917 | 0.081              | 0.923 |
| Ring 5 P1 latency      | 1.495             | 0.246 | 1.430                                       | 0.244 | 1.319              | 0.288 |
| Ring 1 N2 latency      | 2.761             | 0.085 | 0.216                                       | 0.646 | 0.869              | 0.433 |
| Ring 2 N2 latency      | 3.622             | 0.044 | 0.191                                       | 0.666 | 0.095              | 0.910 |
| Ring 3 N2 latency      | 3.053             | 0.068 | <0.001                                      | 0.999 | 1.042              | 0.369 |
| Ring 4 N2 latency      | 1.700             | 0.206 | 1.517                                       | 0.230 | 0.607              | 0.554 |
| Ring 5 N2latency       | 1.490             | 0.247 | 0.057                                       | 0.814 | 0.509              | 0.608 |

2 Table 5a: Mixed between-within ANOVA for mfERG N1P1 amplitude, N1 latency, P1 latency and N2  
3 latency over 3 visits for 5 areas of retinal eccentricity between treated and non-treated groups for  
4 combined HY and HO eyes. The shaded areas indicate statistical significance.

5

1

|                                     |                       | Visit 1      | Visit 2      | Visit 3      |
|-------------------------------------|-----------------------|--------------|--------------|--------------|
|                                     |                       | Mean ± SD    | Mean ± SD    | Mean ± SD    |
| <b>R2 P1 latency</b><br><b>(ms)</b> | Treated (n=15)        | 28.56 ± 1.46 | 28.50 ± 1.48 | 27.89 ± 1.83 |
|                                     | Non-treated<br>(n=10) | 28.25 ± 1.38 | 29.08 ± 1.33 | 28.33 ± 1.24 |
| <b>R2 N2 latency</b><br><b>(ms)</b> | Treated (n=15)        | 42.33 ± 1.84 | 43.06 ± 1.85 | 43.28 ± 1.65 |
|                                     | Non-treated<br>(n=10) | 42.58 ± 1.73 | 43.42 ± 1.21 | 43.42 ± 1.33 |

2 Table 5b: Mean values ± SD for significantly changed mfERG measures between treated and non-  
3 treated healthy eyes over three visits.

4

|                                     | Visit 1      | Visit 2      | Visit 3      |
|-------------------------------------|--------------|--------------|--------------|
|                                     | Mean ± SD    | Mean ± SD    | Mean ± SD    |
| <b>VA (logMAR units)</b>            |              |              |              |
| Treated                             | -0.09 ± 0.09 | -0.07 ± 0.08 | -0.10 ± 0.09 |
| Non-treated                         | -0.12 ± 0.12 | -0.06 ± 0.08 | -0.10 ± 0.09 |
| <b>CS (log units)</b>               |              |              |              |
| Treated                             | 1.88 ± 0.13  | 1.88 ± 0.13  | 1.89 ± 0.12  |
| Non-treated                         | 1.89 ± 0.12  | 1.89 ± 0.12  | 1.92 ± 0.10  |
| <b>MPOD (optical density units)</b> |              |              |              |
| Treated                             | 0.35 ± 0.16  | 0.40 ± 0.14  | 0.45 ± 0.12  |
| Non-treated                         | 0.42 ± 0.16  | 0.42 ± 0.16  | 0.39 ± 0.16  |

5 Table 6: Mean values ± SD between treated and non-treated eyes for VA, CS and MPOD over 3 visits.  
6 The shaded areas indicate statistical significance.

7



1

|  |                  | Treated     | Non-treated |
|--|------------------|-------------|-------------|
| <b>Mean trial duration (months)</b>      | <b>VISIT 1-2</b> | 5.0 ± 0.9   | 4.9 ± 0.7   |
|  | <b>VISIT 1-3</b> | 10.6 ± 1.2  | 10.6 ± 1.4  |
| <b>Mean compliance (% tablets taken)</b> |                  | 79.5 ± 15.9 | N/A         |

2 Table 7: Summary of trial duration (mean ± SD) and participant compliance (% ± SD).

3

4 **Figure legends**

5 Figure 1: A normal mfERG response. The double ended arrow demonstrates N1P1 amplitude (source  
6 - authors own drawing).

7 Figure 2: Grouping of the mfERG areas analysed. Ring 1- red hexagon, ring 2 - beige hexagons, ring  
8 3 - green hexagons, ring 4 - pink hexagons, ring 5 - blue hexagons.

9 Figure 3: Differences between mean MPOD values over three visits between treated and non-treated  
10 groups for healthy eyes.